SELL and COVID-19: We found that all ILC subsets in COVID-19 patients displayed a significantly higher frequency of CD69-expressing-cells compared with healthy controls, accompanied by a decreased frequency of cells expressing CD62L, as was previously noted for ILC2 and ILCps in COVID-19 patients (13).